Edition:
United States

Argos Therapeutics Inc (ARGS.OQ)

ARGS.OQ on NASDAQ Stock Exchange Global Market

4.84USD
23 Sep 2016
Change (% chg)

$-0.10 (-2.02%)
Prev Close
$4.94
Open
$4.92
Day's High
$4.95
Day's Low
$4.82
Volume
26,002
Avg. Vol
62,891
52-wk High
$13.96
52-wk Low
$1.62

ARGS.OQ

Chart for ARGS.OQ

About

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological... (more)

Overall

Beta: --
Market Cap(Mil.): $199.39
Shares Outstanding(Mil.): 41.20
Dividend: --
Yield (%): --

Financials

  ARGS.OQ Industry Sector
P/E (TTM): -- 36.61 36.60
EPS (TTM): -2.86 -- --
ROI: -140.08 14.46 13.91
ROE: -1,402.89 15.26 14.82

Sainsbury's moves swiftly to roll-out Argos digital stores

LONDON, Sept 5 British supermarket group Sainsbury's said on Monday it planned to introduce Argos digital concessions to more than 20 additional stores by Christmas as it seeks to benefit quickly from its purchase of Home Retail.

Sep 05 2016

CORRECTED-BRIEF-Pharmstandard International reports open market purchase of 53,524 shares of Argos Therapeutics at avg price of $4.23/shr

* Pharmstandard International SA reports open market purchase of 53,524 shares of co's common stock at average price of $4.23 per share on Aug. 19

Aug 23 2016

BRIEF-Argos Therapeutics Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S

* Argos Therapeutics reports second quarter 2016 financial results and recent operational highlights

Aug 10 2016

BRIEF-Argos Therapeutics announces proposed public offering of common stock and warrants

* Argos Therapeutics announces proposed public offering of common stock and warrants Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 27 2016

BRIEF-Argos Therapeutics files for common stock offering

* Files for common stock offering of up to 19.5 mln shares by the selling shareholders - SEC filing Source text: (http://bit.ly/2aeNQ2e) Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 22 2016

BRIEF-Argos Therapeutics appoints Richard D. Katz as Chief Financial Officer

* Dr. Richard D. Katz joins Argos Therapeutics as Chief Financial Officer

Jul 11 2016

BRIEF-Argos Therapeutics announces closing of $29.8 mln second tranche of March 2016 financing

* Argos Therapeutics announces closing of $29.8 million second tranche of march 2016 financing Source text for Eikon: Further company coverage: )

Jun 29 2016

BRIEF-Argos Therapeutics enters strategic research agreement with Adaptive Biotechnologies

* Argos Therapeutics enters into strategic research agreement with Adaptive Biotechnologies Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 15 2016

Sainsbury's lines up CFO Rogers to run Home Retail business

LONDON British supermarket Sainsbury's said its finance boss John Rogers would become chief executive of Home Retail when it completes a takeover designed to reduce its reliance on food and drink sales.

Jun 10 2016

Argos owner Home Retail raises provision for overcharging some customers

LONDON Argos owner Home Retail said on Thursday it may need to increase a provision by up to 30 million pounds ($43 million) to compensate financial services customers who were overcharged, taking the shine off its best quarterly trading report for two years.

Jun 09 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.